Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Transient Ischemic Attack Study (POINT)

Clinical Trial Title: 
Platelet-oriented inhibition in new TIA (POINT)
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
James Conners, MD
Clinical Trial Protocol Description: 

The purpose of this study is to determine whether taking Plavix and aspirin for 90 days immediately following a minor stroke or TIA will decrease the risk for another event.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have neurological deficit (based on history or exam) attributed to focal brain ischemia and either of the follwoing apply:
    • Have high-risk TIA: complete resolution of the deficit at the time of randomization and ABCD2 score of (greater than or equal to) 4.
    • Have minor ischemic stroke: residual deficit with NIHSS of (less than or equal to) 3 at the time of randomization.
  • Have ability to randomize within 12 hours of time last known free of new ischemic symptoms.
  • Are able to tolerate aspirin at a dose of 50-325 mg/day.
  • Be over 18 years old.
  • Don't have need for anticoagulation therapy or GI bleeding problems.

This is a partial list of eligibility requirements. 

Clinical Trial Area: 
Stroke and Cerebrovascular Disease
Contact Phone: 
(312) 563-2208
Contact Name: 
Tiffany Singson